Medical Technology

@techcrunch.com 2 years ago

Flagship Pioneering’s new venture is betting on tRNA to treat “thousands of diseases”

@andresvilarino 3 years ago

#ArtificialIntelligence, like #Algorithms, could crack the language of #cancer & #Alzheimer’s, study finds #AI #HealthCare #HealthTech #DigitalHealth #MedicalTech #MedTech #BioTech #ML #MachineLearning #data https://buff.ly/3mFeCos https://t.co/lvl2otB2Du

@xconomy.com 3 years ago

Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin

@xconomy.com 3 years ago

Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More

@xconomy.com 3 years ago

Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity

@xconomy.com 3 years ago

Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity

@xconomy.com 3 years ago

Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More

@xconomy.com 3 years ago

Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue

@xconomy.com 3 years ago

FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures

@xconomy.com 4 years ago

Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More

@xconomy.com 4 years ago

Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More

@xconomy.com 4 years ago

Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks

@xconomy.com 4 years ago

Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer

@xconomy.com 4 years ago

CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019

@xconomy.com 4 years ago

Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More

@xconomy.com 4 years ago

Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus

@xconomy.com 4 years ago

Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers

@xconomy.com 4 years ago

Schrödinger Sets Course for IPO to Support Growing Internal Pipeline

@xconomy.com 4 years ago

Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic

@xconomy.com 4 years ago

Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal

@xconomy.com 4 years ago

Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More

@xconomy.com 4 years ago

ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More

@xconomy.com 4 years ago

Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?

@xconomy.com 4 years ago

Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone

@xconomy.com 4 years ago

Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More